{
  "id": 17762609,
  "title": "GC Biopharma Signs VaxThera Vaccine Deal",
  "url": "https://urgent.news/2026/11/02/gc-biopharma-signs-vaxthera-vaccine-deal",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-02T07:34:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=280215"
  },
  "original_language": "en",
  "account": "On November 2, GC Biopharma announced it had signed a contract with Colombian vaccine company, VaxThera, for technical assistance in the production of their influenza vaccine, GCFLU. The agreement, worth approximately KRW 59.2 billion ($42.95 million), was partially funded by the Research Investment for Global Health Technology Foundation (RIGHT Foundation).\n\nAs part of the collaboration, GC Biopharma will supply the bulk drug substance for GCFLU and offer process technology support for local production and on-site training. In contrast, VaxThera will manage filling, packaging, and quality control at their plant in Colombia. They will also assume responsibility for securing marketing authorization, local distribution, and sales of the product.\n\nGC Biopharma President and CEO, Hur Eun-chul, expressed optimism about the contract, stating it would establish a sustainable supply structure in the Latin American market based on their influenza vaccine technology and production capabilities.\n\nVaxThera's CEO, Jorge E. Osorio, emphasized their commitment to developing local talent through technical support and bolstering health security. Through this partnership, GC Biopharma anticipates enhancing vaccine accessibility in Latin America, while simultaneously fostering a local production ecosystem and establishing a stable revenue model.",
  "summary": "Contract Worth About KRW 59.2 Billion Backed by RIGHT Foundation Funding GC Biopharma said on Nov. 2 that it signed a contract with VaxThera, a Colombian vaccine company, for technical support for finished-product manufacturing and bulk drug substance supply for its influenza vaccine “GCFLU.”The tot",
  "key_points": [
    "GC Biopharma signs KRW 59.2 billion deal with VaxThera for influenza vaccine production.",
    "GC Biopharma supplies bulk drug substance and process technology support.",
    "VaxThera manages filling, packaging, quality control, and local distribution."
  ],
  "editors_take": "This technical partnership allows GC Biopharma to penetrate the Latin American market by leveraging local manufacturing infrastructure to establish a sustainable supply structure for its influenza vaccine.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}